Viewing Study NCT05970302


Ignite Creation Date: 2025-12-25 @ 4:02 AM
Ignite Modification Date: 2026-02-24 @ 5:06 AM
Study NCT ID: NCT05970302
Status: RECRUITING
Last Update Posted: 2023-08-01
First Post: 2023-07-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module